Drug safety
Houston Rx recalls compounded sermorelin and tirzepatide products
The FDA classified Houston Rx’s ongoing recall as Class II, citing a lack of process control.
Houston Rx recalled two injectable products, sermorelin and tirzepatide/niacinamide, over a lack of process control, according to FDA recall records. The FDA classified the recall as Class II and listed its status as ongoing.
The recalled products are sermorelin, 1 mg/mL in a 10 ml vial, and tirzepatide/niacinamide, a 2mL vial containing 40 MG per Vial, with a listed concentration of 20mg/2mg/mL. The products were distributed nationwide. The recall started 2026-09-25, and was reported 2026-10-21.
